MAPK8 and breast carcinoma: Because proteasome inhibitors are a novel class of anti-tumor compounds, and there is evidence that DUSP1 regulates sensitivity to proteasome inhibitors in breast cancer through JNK activity, targeting DUSP1 enhances the anti-tumor efficacy of proteasome inhibitors.121